Summit Therapeutics (SMMT) Return on Sales (2017 - 2023)

Summit Therapeutics (SMMT) has reported Return on Sales for 7 consecutive years, with 27.35% the latest figure, recorded in Q2 2023.

• Quarterly Return on Sales fell 2678.0% year-over-year to 27.35% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 27.35% (down 2695.0% YoY) and the FY2022 annual result came in at 1.12%, down 63.0% from the prior year.
• Return on Sales retreated to 27.35% in Q2 2023 per SMMT's latest filing, from 13.09% in the prior quarter.
• Over the last five years, Return on Sales for SMMT reached as high as 0.01% in Q4 2019 and fell as low as 27.35% in Q2 2023.
• A 5-year average of 2.87% and a median of 0.8% in 2022 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2022 — Return on Sales jumped 372 bps — and 2023, when it slumped 2678 bps.
• Year by year, Return on Sales stood at 0.01% in 2019, then slumped by 8520 bps to 0.73% in 2020, then sank by 48 bps to 1.08% in 2021, then gained by 3 bps to 1.05% in 2022, then tumbled by 2515 bps to 27.35% in 2023.
• According to Business Quant data, Return on Sales over the past three periods registered 27.35%, 13.09%, and 1.05% for Q2 2023, Q1 2023, and Q4 2022 respectively.